- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Not So Different: Kathy Oubre on What Oncology Practices Have Lacked During the Pandemic
We sat down with Kathy Oubre, chief operating officer at the Pontchartrain Cancer Center, to discuss what practices have had to forgo during the coronavirus disease 2019 (COVID-19) crisis and how biosimilar access has been affected.
During 7 months of combatting the coronavirus disease 2019 (COVID-19) pandemic, US health care practices, especially in oncology, had to completely modify how they could safely treat patients. They may have reduced waiting room capacity, barred caregivers from attending appointments with patients, increased telehealth usage, or reworked priorities and postponed decisions.
Some health care experts believe the pandemic will improve the overall uptake of biosimilars because it has made cost savings more important. Many patients face financial hardships as a result of the crisis.
We sat down with Kathy Oubre, chief operating officer at the Pontchartrain Cancer Center in Louisiana, president of the Louisiana Medical Group Management Association, and a member of the board of directors for the Community Oncology Alliance, to discuss what practices had to do without during the COVID-19 crisis and how biosimilar access has been affected.
To learn more about COVID-19’s impact on biosimilars, check out our ebook here.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
